Evidence map›Paper›PMID 41816677›Full record

Trial reportFrontiers in medicine2026

A novel dual elastography-based model for screening high-risk varices in hepatitis B virus-related cirrhosis.

Xing Hu, Min Chen, Ying Zheng, Xiuhua Yang, Wei Zhang, Yao Zhang, Zhiyong Yin, Jintang Liao, Yangshuo Tang, Jie Yu and 2 more

Registry-linked trialAbstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04640350 (Risk Prediction of Bleeding in Liver Cirrhosis by Combi-elastography), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04640350 unknown statusnot on this map

Risk Prediction of Bleeding in Liver Cirrhosis by Combi-elastography

TypeobservationalSponsorChinese PLA General HospitalRan2020 to 2023Enrolled300ConditionsLiver Cirrhosis, Gastroesophageal Varices, Variceal Hemorrhage
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Xing Hu *Center of Ultrasound and Functional Diagnosis, Beijing Youan Hospital, Capital Medical University, Beijing, China.
Min Chen *Department of Ultrasound, Fifth Medical Center of Chinese PLA General Hospital, Beijing, China.
Ying ZhengCenter of Ultrasound and Functional Diagnosis, Beijing Youan Hospital, Capital Medical University, Beijing, China.
Xiuhua YangDepartment of Interventional Ultrasound, The First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China.
Wei ZhangDepartment of Interventional Ultrasound, The First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China.
Yao ZhangDepartment of Ultrasound, Beijing Ditan Hospital, Capital Medical University, Beijing, China.
Zhiyong YinDepartment of Ultrasound, Beijing Ditan Hospital, Capital Medical University, Beijing, China.
Jintang LiaoDepartment of Ultrasound, Xiangya Hospital, Central South University, Changsha, Hunan, China.
Yangshuo TangDepartment of Ultrasound, Xiangya Hospital, Central South University, Changsha, Hunan, China.
Jie YuDepartment of Interventional Ultrasound, Fifth Medical Center of Chinese PLA General Hospital, Beijing, China.
Ping LiangDepartment of Interventional Ultrasound, Fifth Medical Center of Chinese PLA General Hospital, Beijing, China.
Fankun MengCenter of Ultrasound and Functional Diagnosis, Beijing Youan Hospital, Capital Medical University, Beijing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background and objective: Variceal bleeding carries high mortality and recurrence rates, underscoring the urgent need for effective non-invasive tests (NITs) to assess the severity of esophageal varices (EVs) and predict bleeding risk. This study aimed to develop and validate a robust model for safely excluding high-risk varices (HRVs) in patients with hepatitis B virus (HBV)-related cirrhosis and to compare its diagnostic performance and clinical utility with established NITs. Methods: Consecutive patients with HBV-related cirrhosis were prospectively recruited from five centers and underwent dual elastography (dual-elasto) within 1 week of esophagogastroduodenoscopy (EGD). A training cohort from four centers was used to identify predictive variables for HRVs, which were analyzed using machine learning to develop the most reliable model. The final model was externally validated in an independent cohort from the fifth center. Diagnostic efficacy and clinical utility were compared across multiple NITs, including the Baveno VI criteria (B6C), expanded Baveno VI criteria (EB6C), platelet-spleen ratio (PSR), and RESIST-HCV criteria (RESIST). Results: Among 703 screened patients, 328 were enrolled (training cohort Conclusion: DELU is a reliable and safe non-invasive tool for excluding HRVs in HBV-related cirrhosis, providing superior diagnostic accuracy and significant endoscopy-sparing potential across diverse clinical settings. RESIST may serve as a safe alternative when elastography is unavailable. Clinical trial registration: [ClinicalTrials.gov], identifier [NCT04640350].

Indexed as

cirrhosisdual elastographyhepatitis Bhigh-risk varicesnon-invasive test

Identifiers

PMID41816677
PMCPMC12971904

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.